Patents by Inventor Cornelius Pompe

Cornelius Pompe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
    Publication number: 20230192884
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3c? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: July 12, 2022
    Publication date: June 22, 2023
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY CONSTRUCTS
    Publication number: 20230103401
    Abstract: The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.
    Type: Application
    Filed: June 30, 2022
    Publication date: April 6, 2023
    Inventors: Sekhar Kanapuram, Ramil Latypov, Balakumar Thangaraj, Cornelius Pompe
  • SYSTEMS AND APPROACHES FOR DRUG DELIVERY
    Publication number: 20220362104
    Abstract: An approach for determining material compatibility for components of a drug delivery system is provided that includes using surface zeta-potential analytical method to evaluate surface interactions between a desired molecule and at least one material present within a given IV-bag system.
    Type: Application
    Filed: October 23, 2020
    Publication date: November 17, 2022
    Inventors: Cornelius Pompe, Nicholas J. Clark, Wei Qi, Arnold J. McAuley, MIchael Schneider, Chia-Jung Wu, Twinkle R. Christian, Heather N. Franey, Bharadwaj Jagannathan, Jeffrey Abel, Franz Dietzel
  • Bispecific T cell engaging antibody constructs
    Patent number: 11434302
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 6, 2022
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Pharmaceutical composition comprising bispecific antibody constructs
    Patent number: 11419933
    Abstract: The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 23, 2022
    Assignees: AMGEN INC., AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Sekhar Kanapuram, Ramil Latypov, Balakumar Thangaraj, Cornelius Pompe
  • BCMA and CD3 bispecific T cell engaging antibody constructs
    Patent number: 11352433
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 7, 2022
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs
    Publication number: 20210070878
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: August 17, 2020
    Publication date: March 11, 2021
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • LOW PH PHARMACEUTICAL COMPOSITION COMPRISING T CELL ENGAGING ANTIBODY CONSTRUCTS
    Publication number: 20200332000
    Abstract: The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.
    Type: Application
    Filed: February 2, 2018
    Publication date: October 22, 2020
    Inventors: Arnold Mcauley, Pavan Ghattyvenkatakrishna, Jeff Abel, Joon Huh, Cornelius Pompe, Sekhar Kanapuram, Michael Treuheit, Bharadwaj Jagannathan
  • PSMA and CD3 bispecific T cell engaging antibody constructs
    Patent number: 10781264
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 22, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • BCMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
    Publication number: 20200048357
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: April 2, 2019
    Publication date: February 13, 2020
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • BCMA and CD3 bispecific T cell engaging antibody constructs
    Patent number: 10301391
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 28, 2019
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Factor VII composition
    Patent number: 9968662
    Abstract: A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 15, 2018
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Annie Bardat, Cornelius Pompe
  • BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
    Publication number: 20170218078
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • BCMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
    Publication number: 20170218077
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs
    Publication number: 20170218079
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: February 2, 2017
    Publication date: August 3, 2017
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY CONSTRUCTS
    Publication number: 20170209571
    Abstract: The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.
    Type: Application
    Filed: January 25, 2017
    Publication date: July 27, 2017
    Inventors: Sekhar Kanapuram, Ramil Latypov, Balakumar Thangaraj, Cornelius Pompe
  • FACTOR VII COMPOSITION
    Publication number: 20160271233
    Abstract: A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.
    Type: Application
    Filed: May 26, 2016
    Publication date: September 22, 2016
    Inventors: Annie Bardat, Cornelius Pompe
  • Factor VII composition
    Patent number: 9358275
    Abstract: A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: June 7, 2016
    Assignee: Laboratorie Francais du Fractionnement et des Biotechnologies
    Inventors: Annie Bardat, Cornelius Pompe
  • FACTOR VII COMPOSITION
    Publication number: 20150216951
    Abstract: A stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant.
    Type: Application
    Filed: April 15, 2015
    Publication date: August 6, 2015
    Inventors: Annie Bardat, Cornelius Pompe
  • Factor VII composition
    Patent number: 9029316
    Abstract: The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: May 12, 2015
    Assignee: Laboratoire Francais du Fractionnement Et des Biotechnologies
    Inventors: Annie Bardat, Cornelius Pompe